Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Qingjun Jia"'
Autor:
Qingchun Li, Yifei Wu, Qinglin Cheng, Min Lu, Yinyan Huang, Xuexin Bai, Qingjun Jia, Zijian Fang, Liyun Ai, Nan Jiang, QiuFeng Lao, Li Xie, Junfang Chen
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background To assess the prevalence and epidemic pattern of multidrug-resistant tuberculosis in Hangzhou City, Zhejiang Province, China during 2012–2022. Methods All the tuberculosis cases undergoing drug susceptibility testing during 2012
Externí odkaz:
https://doaj.org/article/b6191d04a5dd449387f4db965deec450
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract The study aims to accurately identify differentially expressed genes (DEGs) and biological pathways in mycobacterial infections through bioinformatics for deeper disease understanding. Differentially expressed genes (DEGs) was explored by Ge
Externí odkaz:
https://doaj.org/article/4cf2be84cf3e4ebd94b4519c1ffd2e8f
Autor:
Qinglin Cheng, PhD., Li Xie, Le Wang, Min Lu, Qingchun Li, Yifei Wu, Yinyan Huang, Qingjun Jia, Gang Zhao
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 158-168 (2021)
Objectives: The impact of tuberculosis (TB) history on the risk of multidrug-resistant tuberculosis (MDR-TB) is not yet fully understood. We aimed to identify the impact of different TB history at the onset of future MDR-TB. Methods: A large, retrosp
Externí odkaz:
https://doaj.org/article/db614a47692646afac00d11ade944a5d
Autor:
Yinyan Huang, Yuanyuan Wen, Qingjun Jia, Le Wang, Qinglin Cheng, Wei Liu, Tingting Huang, Li Xie
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 20, Iss , Pp 1-3 (2020)
Objectives: A multidrug-resistant strain of the opportunistic pathogen Streptococcus sanguis (S28) was isolated from a throat swab of a child with scarlet fever as a rare case. Genome sequencing and analysis of strain S28 were performed to gain a bet
Externí odkaz:
https://doaj.org/article/f91baa59858e4f31bf2b666547d4efb4
Autor:
Qinglin Cheng, Li Xie, Le Wang, Min Lu, Qingchun Li, Yifei Wu, Yinyan Huang, Qingjun Jia, Gang Zhao
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Background: To date, too little attention has been paid to monitoring and estimating the risk of incident multidrug-resistant tuberculosis (MDR-TB) among individuals with a previous tuberculosis history (PTBH). The purpose of this study was to assess
Externí odkaz:
https://doaj.org/article/553debb1a6d14289a3085edba330ca97
Publikováno v:
Aging (Albany NY)
Background Many recent studies have investigated the role of drug interventions for coronavirus disease 2019 (COVID-19) infection. However, an important question has been raised about how to select the effective and secure medications for COVID-19 pa
Publikováno v:
Medicine. 101(41)
To date, there has been little agreement on what drug is the "best" drug for treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of different medications available at present for severe COVID-19.We searched databases
Autor:
Meichun Zeng, Qingjun Jia, Jingjing Chen, Liming Xu, Li Xie, Qinglin Cheng, Qingchun Li, Ming Xiao, Zijian Fang
Publikováno v:
Clinical and Experimental Medicine.
The relationship between plasma EBV-DNA load (PEDL) and Epstein-Barr virus (EBV)-encoded small RNA (EBER) during the early treatment of lymphoma remains unclear. We explored discrepancies in PEDL and variables associated with EBER and evaluated the c
Autor:
Qingguo Ren, Shuai Zhao, Rong Yu, Ziliang Xu, Shuangwu Liu, Bin Zhang, Qicai Sun, Qingjun Jiang, Cuiping Zhao, Xiangshui Meng
Publikováno v:
Frontiers in Aging Neuroscience, Vol 16 (2024)
BackgroundLimbic structures have recently garnered increased attention in Parkinson’s disease (PD) research. This study aims to explore changes at the whole-brain level in the structural network, specifically the white matter fibres connecting the
Externí odkaz:
https://doaj.org/article/fc5cbc19667646d8b9deb9fe52d4ee16
Publikováno v:
Journal of medical virology. 94(4)
This study aimed to assess the efficacy and safety of different medications available at present for severe coronavirus disease 2019 (COVID-19) infection. We searched databases for randomized controlled trials (RCTs) published up to April 30, 2021, w